Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Accumulated Expenses (2020 - 2023)

Terns Pharmaceuticals' Accumulated Expenses history spans 4 years, with the latest figure at $3.7 million for Q3 2023.

  • For Q3 2023, Accumulated Expenses rose 85.5% year-over-year to $3.7 million; the TTM value through Sep 2023 reached $3.7 million, up 85.5%, while the annual FY2022 figure was $6.2 million, 156.43% up from the prior year.
  • Accumulated Expenses reached $3.7 million in Q3 2023 per TERN's latest filing, down from $8.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.0 million in Q4 2020 to a low of $499000.0 in Q1 2021.
  • Average Accumulated Expenses over 4 years is $4.3 million, with a median of $3.9 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: tumbled 73.32% in 2021, then soared 1190.57% in 2023.
  • A 4-year view of Accumulated Expenses shows it stood at $9.0 million in 2020, then crashed by 73.32% to $2.4 million in 2021, then surged by 156.43% to $6.2 million in 2022, then plummeted by 40.0% to $3.7 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Accumulated Expenses are $3.7 million (Q3 2023), $8.0 million (Q2 2023), and $8.8 million (Q1 2023).